To read more on this topic click here.
Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs
Author: Simge Eva DoganPublished: 7 November 2018
Prep: Cook: Serves:
Pharmaceutical company Pfizer has teamed with investment firm Bain Capital to launch Cerevel Therapeutics – a biopharmaceutical company focused on developing drugs for Parkinson’s and other central nervous system conditions.
The new company – which will receive US $350 million of investment from Bain Capital – will begin working on phase three clinical trials on a Parkinson’s drug designed to increase levels of dopamine in the brain. Cerevel will also continue to develop several of Pfizer’s drug programmes which closed earlier this year.
Marco Baptista, director of research programmes at The Michael J Fox Foundation – which has partnered with Pfizer since 2010 – said: “This is welcome news for Parkinson’s patients and researchers. Pfizer had developed a diverse group of novel therapeutics for Parkinson’s disease, which are now going to get another chance at success. MJFF looks forward to partnering with Cerevel to support the advancement of these promising programs.”
For more information on Parkinson’s treatments please visit Parkinson’s Europe website
AI technology could diagnose Parkinson’s in less than three minutes
New smart glasses could track Parkinson’s symptoms
Share this story
The campaign calling for “proper” Parkinson’s disease care in Ireland
Is there a lack of specialist support?READ MORE
“We never stop” – launching Parkinson Games
A global sporting event for Parkinson’s disease communityREAD MORE
Health & Fitness
Together, apart: tune in to a World Parkinson’s Day video event
A chance for people with Parkinson's disease to “learn and get inspired"READ MORE